Product Watch

Strides Arcolab gets USFDA approval for anti-bacterial injection

Views: 498


Drug firm Strides Arcolab said it has received the US health regulator’s approval to market injectable Clindamycin USP, used in the treatment of bacterial infections, in the American market.
The product will be available in three single-dose vial sizes and in pharmacy bulk packaging, Strides Arcolab said in a statement.
“The product is expected to be launched in early 2012,” it said, adding that the company received approval for its Clindamycin USP from the US Food and Drug Administration (USFDA).

Click to comment

Leave a Reply

Your email address will not be published.

Most Popular

 

 


 

 

Get Heard Portal

 

eHealth Event Report

 

 

To Top